AcquisitionOther

Synthetic Biologics, Inc. acquired VCN Biosciences, S.L

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

Synthetic Biologics, Inc. -> VCN Biosciences, S.L

VCN is a privately held clinical-stage biotech company focused on developing a new oncolytic adenovirus (OV) platform designed for intravenous (IV) and intravitreal (IVit) delivery to trigger tumor cell death, improve access of co-administered cancer therapies

Open source record (SEC) ↗